Substance / Medication

Medrysone

Overview

Active Ingredient
medrysone
RxNorm CUI
29439

Indications

® HMS(medrysone ophthalmic suspension) is indicated for the treatment of allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity.

Labeler: Allergan, Inc.Updated: 2006-02-28T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

® ® HMSsuspension is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. HMSsuspension is

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Safety, effectiveness, and acceptability of antenatal penicillin allergy evaluation: a systematic review.
Reddeman Lindsay, Lim Justin W J, Murphy Kellie E et al. · Am J Obstet Gynecol · 2026
PMID: 40886786Meta-Analysis
Risk factors associated with immediate hypersensitivity reaction to contrast media: a systematic review and meta-analysis.
Huang Wenyu, He Chunlei, Chen Yuntian et al. · Eur J Radiol · 2026
PMID: 41175815Meta-Analysis
Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus.
Wang Yun, Wang Sihe, Wang Wei et al. · Diabetes Obes Metab · 2026
PMID: 41344910Meta-AnalysisFull text (PMC)
Safety of indocyanine green for lymph node mapping in early-stage vulvar cancer: multicenter evaluation and systematic review.
Guijarro-Campillo Alberto Rafael, Padilla-Iserte Pablo, Couso Bárbara et al. · Arch Gynecol Obstet · 2026
PMID: 41533021Meta-AnalysisFull text (PMC)
Substituting with alternative iodinated contrast medium to prevent recurrent adverse drug reactions associated with its use: a meta-analysis.
Lim Su Jin, Suh Pae Sun, Suh Chong Hyun et al. · Eur Radiol · 2025
PMID: 39419863Meta-Analysis
A systematic review and meta-analysis of interventions to delabel low-risk penicillin allergies with consideration for sex and gender.
Maximos Mira, Pelletier Ryan, Elsayed Sameer et al. · Br J Clin Pharmacol · 2025
PMID: 39702887Meta-AnalysisFull text (PMC)
Risk Factors of Hypersensitivity Reactions to Carboplatin: A Systematic Review and Meta-Analysis.
Jang Ha Young, Choi Boyoon, Kim In-Wha et al. · J Allergy Clin Immunol Pract · 2025
PMID: 39725314Meta-Analysis
The global prevalence of reported penicillin allergy: A systematic review and meta-analysis.
Luintel Akish, Healy Joseph, Blank Michael et al. · J Infect · 2025
PMID: 39874990Meta-Analysis
Adverse Reactions to Urinary Contrast: A Case Report and Systematic Review.
Xu Shuang, Watson Nicholas, Wang Li et al. · J Med Imaging Radiat Oncol · 2025
PMID: 40096376Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Medrysone (substance)
SNOMED CT
387403005
UMLS CUI
C0065865
RxNorm CUI
29439
Labeler
Allergan, Inc.

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.